Serum Anti-Mullerian Hormone Levels Might Indicate Premenopausal Endometrial Lesions

被引:0
作者
Yao, Yingsha [1 ]
Shi, Liujing [1 ]
Zhu, Xiaoming [1 ,2 ]
机构
[1] Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou 310006, Peoples R China
[2] Zhejiang Univ, Womens Hosp, Sch Med, Key Lab Womens Reprod Hlth Zhejiang Prov, Hangzhou 310006, Peoples R China
关键词
polycystic ovary syndrome; endometrial proliferative lesions; anti-Mullerian hormone; threshold value; regression model; POLYCYSTIC-OVARY-SYNDROME; CANCER STATISTICS; RISK; HYPERPLASIA; ULTRASOUND; PREDICTION; CONSENSUS; CRITERIA; CA125; HE-4;
D O I
10.3390/diagnostics13213301
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Endometrial proliferative lesions (EPL) usually refer to endometrial hyperplasia (EH) and endometrial cancer (EC). Among patients with premenopausal EPL who wish to preserve their fertility, only those with EH and early-stage EC have the possibility to undergo fertility preservation therapy. However, there is currently a lack of specific and reliable screening criteria and models for identifying these patients. Methods: This study utilized a retrospective diagnostic study design. The training set included medical record information that met the criteria between August 2017 and October 2022, while the validation set consisted of medical record information that met the criteria from November 2022 to May 2023. The endometrial pathological test served as the gold standard. The serum anti-Mullerian hormone (AMH) level before endometrial sampling and a regression model were employed to predict EPL. Results: The study included a total of 1209 patients with PCOS (1119 in the control group and 90 in the endometrial proliferative lesion group) and 5366 women without PCOS (5249 in the control group and 117 in the proliferative lesion group). In the case of PCOS patients aged 20-39 years, the most effective screening threshold for AMH was found to be a serum AMH level of <= 5.39 ng/mL. The model used for this group was logit(p) = -2.562 - 0.430 x AMH + 0.127 x BMI + 1.512 x hypertension + 0.956 x diabetes -1.145 x regular menstruation. On the other hand, for non-PCOS women aged 20-39 years, the optimal screening threshold for AMH was determined to be a serum AMH value of <= 2.18 ng/mL. The model used for this group was logit(p) = -3.778 - 0.823 x AMH + 0.176 x BMI + 2.660 x diabetes -1.527 x regular menstruation -1.117 x dysmenorrhea. It is important to note that all of these findings have successfully passed internal verification. Conclusion: For PCOS and non-PCOS women aged 20-39 years, the serum AMH test and related multiple regression models were obtained for the warning of EPL.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Comparison of two different anti-mullerian hormone measurement methods and evaluation of anti-mullerian hormone in polycystic ovary syndrome
    Gok, Gamze
    Bal, Ceylan
    Secen, Elcin Islek
    Desdicioglu, Raziye
    Akbiyik, Filiz
    Yilmaz, Gulsen
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2025,
  • [42] Serum anti-Mullerian hormone as a predictor of polycystic ovarian syndrome among women of reproductive age
    Butt, Muhammad Salman
    Saleem, Javeria
    Aiman, Sobia
    Zakar, Rubeena
    Sadique, Iftikhar
    Fischer, Florian
    BMC WOMENS HEALTH, 2022, 22 (01)
  • [43] The effect of medication on serum anti-mullerian hormone (AMH) levels in women of reproductive age: a meta-analysis
    Yin, Wei-Wei
    Huang, Chang-Chang
    Chen, Yi-Ru
    Yu, Dan-Qing
    Jin, Min
    Feng, Chun
    BMC ENDOCRINE DISORDERS, 2022, 22 (01)
  • [44] Current Knowledge of Anti-Mullerian Hormone (AMH)
    Scheffer, Juliano Brum
    Brum Scheffer, Rafaela Friche
    Pimenta, Erika Lima
    Scheffer, Bruno Brum
    JORNAL BRASILEIRO DE REPRODUCAO ASSISTIDA, 2011, 15 (05): : 44 - 48
  • [45] Anti-Mullerian hormone and polycystic ovary syndrome
    Catteau-Jonard, S.
    Dewailly, D.
    GYNECOLOGIE OBSTETRIQUE & FERTILITE, 2011, 39 (09): : 514 - 517
  • [46] Clinical Utility of Anti-Mullerian Hormone in Pediatrics
    Shankar, Roopa Kanakatti
    Dowlut-McElroy, Tazim
    Dauber, Andrew
    Gomez-Lobo, Veronica
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2022, 107 (02) : 309 - 323
  • [47] Anti-Mullerian hormone - a predictor of ovarian reserve
    Meden-Vrtovec, Helena
    Osredkar, Josko
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2010, 79 (06): : 507 - 511
  • [48] High levels of anti-Mullerian hormone: what does this mean for IVF treatment?
    Holte, Jan
    Brodin, Thomas
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2013, 8 (03) : 209 - 211
  • [49] Anti-Mullerian hormone: Player and marker of folliculogenesis
    da Silva, A. -L Berwanger
    Even, M.
    Grynberg, M.
    Gallot, V.
    Frydman, R.
    Fanchin, R.
    GYNECOLOGIE OBSTETRIQUE & FERTILITE, 2010, 38 (7-8): : 471 - 474
  • [50] Determining the age group-based cut-off values of serum anti-Mullerian hormone concentrations to diagnose polycystic ovary syndrome
    Timur, Hikmet Tunc
    Cimrin, Dilek
    Doruk, Ozlem Gursoy
    Dogan, Omer Erbil
    CURRENT MEDICAL RESEARCH AND OPINION, 2023, 39 (06) : 855 - 863